Pygeum is a botanical supplement from African cherry bark, administered orally by aging men to support urinary comfort, bladder emptying, and sleep. High-level, conflicted evidence shows modest improvements in urinary symptoms, nighttime urination, urinary flow, and residual bladder volume in mild-to-moderate prostate enlargement. Evidence for prostate inflammation and hair loss is low, other uses are speculative, mild adverse events match placebo, and supplement quality varies. (Full Review)
| Marker | Target | Why |
|---|---|---|
| International Prostate Symptom Score (IPSS) | ≤ 7 points (mild symptom band per Chatelain et al., 1999) | Efficacy marker expected to decrease with treatment. |
| Peak Urinary Flow Rate (Qmax) | No established target; track increase from individual baseline (≥ 1.6–2.5 mL/s gain in trials) | Efficacy marker expected to increase with treatment. |
| Post-Void Residual (PVR) Urine Volume | No established target; track reduction from individual baseline (~13 mL or 24% drop in trials) | Efficacy marker expected to decrease with treatment. |
| Serum Prostate-Specific Antigen (PSA) | ≤ 1.0 ng/mL (Life Extension optimal target) | Safety check to exclude undetected prostate cancer. |
| Serum Alanine Aminotransferase (ALT) & Creatinine | ALT: 7–56 U/L; Creatinine: 0.7–1.3 mg/dL (standard reference range) | Safety check to rule out hepatic or renal stress. |
Cadence: Baseline testing (IPSS, 3-day nocturnal voiding diary, Qmax, PVR volume, and fasting morning serum PSA, ALT, and creatinine), followed by reassessment at 8 weeks, 6 months, and every 6–12 months thereafter during continuous use (repeating ALT and creatinine for high-dose regimens).